Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

Marco L. Davila, Isabelle Riviere, Xiuyan Wang, Shirley Bartido, Jae Park, Kevin Curran, Stephen S. Chung, Jolanta Stefanski, Oriana Borquez-Ojeda, Malgorzata Olszewska, Jinrong Qu, Teresa Wasielewska, Qing He, Mitsu Fink, Himaly Shinglot, Maher Youssif, Mark Satter, Yongzeng Wang, James Hosey, Hilda QuintanillaElizabeth Halton, Yvette Bernal, Diana C.G. Bouhassira, Maria E. Arcila, Mithat Gonen, Gail J. Roboz, Peter Maslak, Dan Douer, Mark G. Frattini, Sergio Giralt, Michel Sadelain, Renier Brentjens

Research output: Contribution to journalArticle

1106 Citations (Scopus)

Abstract

We report on 16 patients with relapsed or refractory B cell acute lymphoblastic leukemia (B-ALL) that we treated with autologous T cells expressing the 19-28z chimeric antigen receptor (CAR) specific to the CD19 antigen. The overall complete response rate was 88%, which allowed us to transition most of these patients to a standard-of-care allogeneic hematopoietic stem cell transplant (allo-SCT). This therapy was as effective in high-risk patients with Philadelphia chromosome-positive (Ph+) disease as in those with relapsed disease after previous allo-SCT. Through systematic analysis of clinical data and serum cytokine levels over the first 21 days after T cell infusion, we have defined diagnostic criteria for a severe cytokine release syndrome (sCRS), with the goal of better identifying the subset of patients who will likely require therapeutic intervention with corticosteroids or interleukin-6 receptor blockade to curb the sCRS. Additionally, we found that serum C-reactive protein, a readily available laboratory study, can serve as a reliable indicator for the severity of the CRS. Together, our data provide strong support for conducting a multicenter phase 2 study to further evaluate 19-28z CAR T cells in B-ALL and a road map for patient management at centers now contemplating the use of CAR T cell therapy.

Original languageEnglish (US)
Article number224ra25
JournalScience Translational Medicine
Volume6
Issue number224
DOIs
StatePublished - Feb 19 2014
Externally publishedYes

Fingerprint

Antigen Receptors
Cell- and Tissue-Based Therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Lymphocytes
Cytokines
Hematopoietic Stem Cells
CD19 Antigens
T-Lymphocytes
Transplants
Interleukin-6 Receptors
Patient Transfer
Philadelphia Chromosome
Standard of Care
T-Cell Antigen Receptor
C-Reactive Protein
Blood Proteins
Adrenal Cortex Hormones
Therapeutics
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., ... Brentjens, R. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science Translational Medicine, 6(224), [224ra25]. https://doi.org/10.1126/scitranslmed.3008226

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. / Davila, Marco L.; Riviere, Isabelle; Wang, Xiuyan; Bartido, Shirley; Park, Jae; Curran, Kevin; Chung, Stephen S.; Stefanski, Jolanta; Borquez-Ojeda, Oriana; Olszewska, Malgorzata; Qu, Jinrong; Wasielewska, Teresa; He, Qing; Fink, Mitsu; Shinglot, Himaly; Youssif, Maher; Satter, Mark; Wang, Yongzeng; Hosey, James; Quintanilla, Hilda; Halton, Elizabeth; Bernal, Yvette; Bouhassira, Diana C.G.; Arcila, Maria E.; Gonen, Mithat; Roboz, Gail J.; Maslak, Peter; Douer, Dan; Frattini, Mark G.; Giralt, Sergio; Sadelain, Michel; Brentjens, Renier.

In: Science Translational Medicine, Vol. 6, No. 224, 224ra25, 19.02.2014.

Research output: Contribution to journalArticle

Davila, ML, Riviere, I, Wang, X, Bartido, S, Park, J, Curran, K, Chung, SS, Stefanski, J, Borquez-Ojeda, O, Olszewska, M, Qu, J, Wasielewska, T, He, Q, Fink, M, Shinglot, H, Youssif, M, Satter, M, Wang, Y, Hosey, J, Quintanilla, H, Halton, E, Bernal, Y, Bouhassira, DCG, Arcila, ME, Gonen, M, Roboz, GJ, Maslak, P, Douer, D, Frattini, MG, Giralt, S, Sadelain, M & Brentjens, R 2014, 'Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia', Science Translational Medicine, vol. 6, no. 224, 224ra25. https://doi.org/10.1126/scitranslmed.3008226
Davila, Marco L. ; Riviere, Isabelle ; Wang, Xiuyan ; Bartido, Shirley ; Park, Jae ; Curran, Kevin ; Chung, Stephen S. ; Stefanski, Jolanta ; Borquez-Ojeda, Oriana ; Olszewska, Malgorzata ; Qu, Jinrong ; Wasielewska, Teresa ; He, Qing ; Fink, Mitsu ; Shinglot, Himaly ; Youssif, Maher ; Satter, Mark ; Wang, Yongzeng ; Hosey, James ; Quintanilla, Hilda ; Halton, Elizabeth ; Bernal, Yvette ; Bouhassira, Diana C.G. ; Arcila, Maria E. ; Gonen, Mithat ; Roboz, Gail J. ; Maslak, Peter ; Douer, Dan ; Frattini, Mark G. ; Giralt, Sergio ; Sadelain, Michel ; Brentjens, Renier. / Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. In: Science Translational Medicine. 2014 ; Vol. 6, No. 224.
@article{40a9fc4136934c509f6994ff88bfdd94,
title = "Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia",
abstract = "We report on 16 patients with relapsed or refractory B cell acute lymphoblastic leukemia (B-ALL) that we treated with autologous T cells expressing the 19-28z chimeric antigen receptor (CAR) specific to the CD19 antigen. The overall complete response rate was 88{\%}, which allowed us to transition most of these patients to a standard-of-care allogeneic hematopoietic stem cell transplant (allo-SCT). This therapy was as effective in high-risk patients with Philadelphia chromosome-positive (Ph+) disease as in those with relapsed disease after previous allo-SCT. Through systematic analysis of clinical data and serum cytokine levels over the first 21 days after T cell infusion, we have defined diagnostic criteria for a severe cytokine release syndrome (sCRS), with the goal of better identifying the subset of patients who will likely require therapeutic intervention with corticosteroids or interleukin-6 receptor blockade to curb the sCRS. Additionally, we found that serum C-reactive protein, a readily available laboratory study, can serve as a reliable indicator for the severity of the CRS. Together, our data provide strong support for conducting a multicenter phase 2 study to further evaluate 19-28z CAR T cells in B-ALL and a road map for patient management at centers now contemplating the use of CAR T cell therapy.",
author = "Davila, {Marco L.} and Isabelle Riviere and Xiuyan Wang and Shirley Bartido and Jae Park and Kevin Curran and Chung, {Stephen S.} and Jolanta Stefanski and Oriana Borquez-Ojeda and Malgorzata Olszewska and Jinrong Qu and Teresa Wasielewska and Qing He and Mitsu Fink and Himaly Shinglot and Maher Youssif and Mark Satter and Yongzeng Wang and James Hosey and Hilda Quintanilla and Elizabeth Halton and Yvette Bernal and Bouhassira, {Diana C.G.} and Arcila, {Maria E.} and Mithat Gonen and Roboz, {Gail J.} and Peter Maslak and Dan Douer and Frattini, {Mark G.} and Sergio Giralt and Michel Sadelain and Renier Brentjens",
year = "2014",
month = "2",
day = "19",
doi = "10.1126/scitranslmed.3008226",
language = "English (US)",
volume = "6",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "224",

}

TY - JOUR

T1 - Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

AU - Davila, Marco L.

AU - Riviere, Isabelle

AU - Wang, Xiuyan

AU - Bartido, Shirley

AU - Park, Jae

AU - Curran, Kevin

AU - Chung, Stephen S.

AU - Stefanski, Jolanta

AU - Borquez-Ojeda, Oriana

AU - Olszewska, Malgorzata

AU - Qu, Jinrong

AU - Wasielewska, Teresa

AU - He, Qing

AU - Fink, Mitsu

AU - Shinglot, Himaly

AU - Youssif, Maher

AU - Satter, Mark

AU - Wang, Yongzeng

AU - Hosey, James

AU - Quintanilla, Hilda

AU - Halton, Elizabeth

AU - Bernal, Yvette

AU - Bouhassira, Diana C.G.

AU - Arcila, Maria E.

AU - Gonen, Mithat

AU - Roboz, Gail J.

AU - Maslak, Peter

AU - Douer, Dan

AU - Frattini, Mark G.

AU - Giralt, Sergio

AU - Sadelain, Michel

AU - Brentjens, Renier

PY - 2014/2/19

Y1 - 2014/2/19

N2 - We report on 16 patients with relapsed or refractory B cell acute lymphoblastic leukemia (B-ALL) that we treated with autologous T cells expressing the 19-28z chimeric antigen receptor (CAR) specific to the CD19 antigen. The overall complete response rate was 88%, which allowed us to transition most of these patients to a standard-of-care allogeneic hematopoietic stem cell transplant (allo-SCT). This therapy was as effective in high-risk patients with Philadelphia chromosome-positive (Ph+) disease as in those with relapsed disease after previous allo-SCT. Through systematic analysis of clinical data and serum cytokine levels over the first 21 days after T cell infusion, we have defined diagnostic criteria for a severe cytokine release syndrome (sCRS), with the goal of better identifying the subset of patients who will likely require therapeutic intervention with corticosteroids or interleukin-6 receptor blockade to curb the sCRS. Additionally, we found that serum C-reactive protein, a readily available laboratory study, can serve as a reliable indicator for the severity of the CRS. Together, our data provide strong support for conducting a multicenter phase 2 study to further evaluate 19-28z CAR T cells in B-ALL and a road map for patient management at centers now contemplating the use of CAR T cell therapy.

AB - We report on 16 patients with relapsed or refractory B cell acute lymphoblastic leukemia (B-ALL) that we treated with autologous T cells expressing the 19-28z chimeric antigen receptor (CAR) specific to the CD19 antigen. The overall complete response rate was 88%, which allowed us to transition most of these patients to a standard-of-care allogeneic hematopoietic stem cell transplant (allo-SCT). This therapy was as effective in high-risk patients with Philadelphia chromosome-positive (Ph+) disease as in those with relapsed disease after previous allo-SCT. Through systematic analysis of clinical data and serum cytokine levels over the first 21 days after T cell infusion, we have defined diagnostic criteria for a severe cytokine release syndrome (sCRS), with the goal of better identifying the subset of patients who will likely require therapeutic intervention with corticosteroids or interleukin-6 receptor blockade to curb the sCRS. Additionally, we found that serum C-reactive protein, a readily available laboratory study, can serve as a reliable indicator for the severity of the CRS. Together, our data provide strong support for conducting a multicenter phase 2 study to further evaluate 19-28z CAR T cells in B-ALL and a road map for patient management at centers now contemplating the use of CAR T cell therapy.

UR - http://www.scopus.com/inward/record.url?scp=84896335556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896335556&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3008226

DO - 10.1126/scitranslmed.3008226

M3 - Article

C2 - 24553386

AN - SCOPUS:84896335556

VL - 6

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 224

M1 - 224ra25

ER -